

FORM PTO-1390
(REV 12-29-99)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

2560USOP

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/807647

INTERNATIONAL APPLICATION NO.
PCT/JP99/05754INTERNATIONAL FILING DATE
October 19, 1999PRIORITY DATE CLAIMED
October 20, 1998

TITLE OF INVENTION

1,5-Benzodiazepine Compounds, Their Production and Use

APPLICANT(S) FOR DO/EO/US

Satoru Oi et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)). *
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 - 1) Sequence Listing (Paper & Computer-readable copies)
 - 2) Sequence Listing Statement

* This includes specification 221 total pages, including Claims 1-18 (9 pgs), Abstract (1 pg), and Sequence listing (4 pgs).

Form PTO-1390 (REV. 12-29-99) page 2 of 2

09/807647
Rec'd PCT/PAO 16 APR 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: tba	Art Unit: tba
Filed: tba	Examiner: tba
1 st Inventor: Satoru OI	Allowed:
For: 1.5-Benzodiazepine Compounds, Their Production and Use	Batch:
Atty. Dkt. No. 2560 USOP	Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EL 784119258 US

DATE IN: April 16, 2001


Itemized Papers/Items:

1. This certificate and a Return Receipt Postcard (2 pgs.)
2. Transmittal Letter for Filing under 35 USC 371 (2 pgs. X 2)
3. English Translation of the International Application as filed in Japanese [This includes Specification 221 total pages, including Claims 1-18 (9 pgs.), Abstract (1 pg.) and Sequence Listing (4 pgs.)]
4. Executed Declaration/Power of Attorney (4 pgs.)
5. Information Disclosure Statement (2 pgs.) with PTO form 1449 (1 pg.), and copies of IDS citations (6), and the International Search Report (2 pgs.)
6. Executed Assignment (2 pgs.) and assignment cover sheet (1 pg. X 2)
7. Sequence Listing Statement (1 pg.)
8. Sequence Listing (Paper & Computer-readable copies) (2 pgs.)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

BOX PCT
Commissioner for Patents
Washington, D.C. 20231.

on this date, 4/16/01.



Dated: Gail L. Winokur